Sigma Of Australia Inks Due-Diligence Pact With Suitor Aspen
This article was originally published in PharmAsia News
Executive Summary
Australia's Sigma Pharmaceuticals moved closer to its acquisition by South Africa's Aspen Pharmacare as the two firms agreed on due-diligence procedures that could lead to closing the $591 million deal